I 
117TH CONGRESS 
1ST SESSION H. R. 6150 
To amend the Controlled Substances Act to require the Attorney General 
to make procurement quotas for opioid analgesics publicly available, 
and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
DECEMBER 7, 2021 
Mr. CICILLINE (for himself, Mr. FITZPATRICK, and Mr. MOULTON) introduced 
the following bill; which was referred to the Committee on Energy and 
Commerce, and in addition to the Committee on the Judiciary, for a pe-
riod to be subsequently determined by the Speaker, in each case for con-
sideration of such provisions as fall within the jurisdiction of the com-
mittee concerned 
A BILL 
To amend the Controlled Substances Act to require the At-
torney General to make procurement quotas for opioid 
analgesics publicly available, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Opioid Quota Open-
ness, Transparency, and Awareness Act of 2021’’ or the 
‘‘Opioid QuOTA Act of 2021’’. 
VerDate Sep 11 2014 
16:32 Jan 10, 2022
Jkt 029200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H6150.IH
H6150
pamtmann on DSKBC07HB2PROD with BILLS
SEC. 2. PUBLIC REPORTING OF PROCUREMENT QUOTAS 
FOR OPIOID ANALGESICS. 
(a) IN GENERAL.—Section 306 of the Controlled 
Substances Act (21 U.S.C. 826) is amended by adding at 
the end the following: 
‘‘(j)(1) In this subsection, the term ‘opioid procure-
ment quota’ means a quota established by the Attorney 
General for the quantity of opioid analgesics that a reg-
istered manufacturer may procure for purposes of manu-
facturing dosage forms or other substances. 
‘‘(2) The Attorney General shall make publicly avail-
able, including through the website of the Drug Enforce-
ment Administration— 
‘‘(A) the quantity of the opioid procurement 
quota for each registered manufacturer for each 
year; 
‘‘(B) the quantity of opioid analgesics procured 
by each registered manufacturer for each year; and 
‘‘(C) except as provided under paragraph (3)— 
‘‘(i) a copy of the form or other applica-
tion, including any attachments or exhibits, 
submitted by each registered manufacturer re-
questing an opioid procurement quota; and 
‘‘(ii) a copy of each year-end or annual re-
port relating to the procurement or use of 
opioid analgesics submitted to the Attorney 
VerDate Sep 11 2014 
16:32 Jan 10, 2022
Jkt 029200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H6150.IH
H6150
pamtmann on DSKBC07HB2PROD with BILLS
General by a registered manufacturer to whom 
the Attorney General has issued an opioid pro-
curement quota. 
‘‘(3)(A) Upon request by a registered manufacturer, 
the Attorney General may redact information identified in 
clause (i) or (ii) of paragraph (2)(C) from the publication 
required under paragraph (2) if the Attorney General de-
termines that public disclosure of that information is likely 
to cause substantial harm to the competitive position of 
the registered manufacturer. For purposes of a determina-
tion under this subparagraph, adverse publicity or embar-
rassment shall not constitute competitive harm. 
‘‘(B) A determination of the Attorney General under 
subparagraph (A) shall be subject to judicial review in ac-
cordance with chapter 7 of title 5, United States Code. 
‘‘(C) The Attorney General shall annually publish a 
report on the website of the Department of Justice con-
taining an accounting of each declination determination 
made under subparagraph (A), including the reason for 
the declination, during the time period covered by the re-
port.’’. 
(b) GAO REPORT.—The Comptroller General of the 
United States shall submit to Congress a report that, for 
the 1-year period beginning on the date of enactment of 
this Act— 
VerDate Sep 11 2014 
16:32 Jan 10, 2022
Jkt 029200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H6150.IH
H6150
pamtmann on DSKBC07HB2PROD with BILLS
(1) details— 
(A) the number of instances in which a 
registered manufacturer made a request de-
scribed in section 306(j)(3) of the Controlled 
Substances Act, as added by subsection (a), 
with respect to a document or information; and 
(B) the number of instances in which the 
Attorney General redacted information de-
scribed in clause (i) or (ii) of subsection 
(j)(2)(C) of the Controlled Substances Act, as 
added by subsection (a), from the publication 
required under such subsection (j)(2); and 
(2) evaluates, in a fair, compliant, and trans-
parent manner, the extent of the independent eval-
uation conducted by the Attorney General of re-
quests described in section 306(j)(3) of the Con-
trolled Substances Act, as added by subsection (a). 
Æ 
VerDate Sep 11 2014 
16:32 Jan 10, 2022
Jkt 029200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\H6150.IH
H6150
pamtmann on DSKBC07HB2PROD with BILLS